Compare Boston Scientific Corporation (BSX) vs Centrus Energy Corp (LEU) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Centrus Energy (LEU) trades at $186.93, down 1.27% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating earnings estimates but showing margin compression. LEU maintains a strong $4.5 billion backlog and secured significant DOE funding, positioning it as a key player in the domestic nuclear fuel supply chain. Valuation metrics appear elevated with a P/E of 68.23 and P/S of 8.89, reflecting growth expectations in the nuclear energy sector.

The outlook remains positive given government support for nuclear energy and Centrus's strategic position in HALEU production. However, investors face risks from execution challenges, cost pressures, and the capital-intensive nature of enrichment facility expansion. Analyst consensus leans bullish with a $228.50 price target, though the stock's premium valuation requires careful monitoring of operational milestones and margin trends.